Literature DB >> 16702226

Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.

Jan Balzarini1, Sandra Liekens, Nicola Solaroli, Kamel El Omari, David K Stammers, Anna Karlsson.   

Abstract

Studies of herpes simplex virus type 1 (HSV-1) thymidine (dThd) kinase (TK) crystal structures show that purine and pyrimidine bases occupy distinct positions in the active site but approximately the same geometric plane. The presence of a bulky side chain, such as tyrosine at position 167, would not be sterically favorable for pyrimidine or pyrimidine nucleoside analogue binding, whereas purine nucleoside analogues would be less affected because they are located further away from the phenylalanine side chain. Site-directed mutagenesis of the conserved Ala-167 and Ala-168 residues in HSV-1 TK resulted in a wide variety of differential affinities and catalytic activities in the presence of the natural substrate dThd and the purine nucleoside analogue drug ganciclovir (GCV), depending on the nature of the amino acid mutation. A168H- and A167F-mutated HSV-1 TK enzymes turned out to have a virtually complete knock-out of dThd kinase activity (at least approximately 4-5 orders of magnitude lower) presumably due to a steric clash between the mutated amino acid and the dThd ring. In contrast, a full preservation of the GCV (and other purine nucleoside analogues) kinase activity was achieved for A168H TK. The enzyme mutants also markedly lost their binding capacity for dThd and showed a substantially diminished feedback inhibition by thymidine 5'-triphosphate. The side chain size at position 168 seems to play a less important role regarding GCV or dThd selectivity than at position 167. Instead, the nitrogen-containing side chains from A168H and A168K seem necessary for efficient ligand discrimination. This explains why A168H-mutated HSV-1 TK fully preserves its GCV kinase activity (Vmax/Km 4-fold higher than wild-type HSV-1 TK), although still showing a severely compromised dThd kinase activity (Vmax/Km 3-4 orders of magnitude lower than wild-type HSV-1 TK).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702226     DOI: 10.1074/jbc.M600414200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

Review 2.  Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Authors:  Andressa Ardiani; Adam J Johnson; Hongmei Ruan; Marilyn Sanchez-Bonilla; Kinta Serve; Margaret E Black
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

3.  Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.

Authors:  Ellen Preuss; Alexander Muik; Kristoffer Weber; Jürgen Otte; Dorothee von Laer; Boris Fehse
Journal:  J Mol Med (Berl)       Date:  2011-06-23       Impact factor: 4.599

4.  Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses.

Authors:  N Coen; U Singh; V Vuyyuru; J J Van den Oord; J Balzarini; S Duraffour; R Snoeck; Y C Cheng; C K Chu; G Andrei
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

5.  A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation.

Authors:  S T Gammon; M Bernstein; D P Schuster; D Piwnica-Worms
Journal:  Anal Biochem       Date:  2007-06-15       Impact factor: 3.365

6.  Early stem cell engraftment predicts late cardiac functional recovery: preclinical insights from molecular imaging.

Authors:  Junwei Liu; Kazim H Narsinh; Feng Lan; Li Wang; Patricia K Nguyen; Shijun Hu; Andrew Lee; Leng Han; Yongquan Gong; Mei Huang; Divya Nag; Jarrett Rosenberg; Alexandra Chouldechova; Robert C Robbins; Joseph C Wu
Journal:  Circ Cardiovasc Imaging       Date:  2012-05-07       Impact factor: 7.792

7.  Improving the Safety of Mesenchymal Stem Cell-Based Ex Vivo Therapy Using Herpes Simplex Virus Thymidine Kinase.

Authors:  Narayan Bashyal; Tae-Young Lee; Da-Young Chang; Jin-Hwa Jung; Min Gyeong Kim; Rakshya Acharya; Sung-Soo Kim; Il-Hoan Oh; Haeyoung Suh-Kim
Journal:  Mol Cells       Date:  2022-03-21       Impact factor: 4.250

8.  Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases.

Authors:  Tomoya Oishi; Masahiko Ito; Shinichiro Koizumi; Makoto Horikawa; Taisuke Yamamoto; Satoru Yamagishi; Tomohiro Yamasaki; Tetsuro Sameshima; Tetsuro Suzuki; Haruhiko Sugimura; Hiroki Namba; Kazuhiko Kurozumi
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-06       Impact factor: 5.849

9.  Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.

Authors:  Lei-qing Li; Fang Shen; Xiao-yan Xu; Hong Zhang; Xiao-feng Yang; Wei-guo Liu
Journal:  ScientificWorldJournal       Date:  2013-03-03

10.  The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity.

Authors:  Willmon Candice L; Sussman Django; Black Margaret E
Journal:  Open Biochem J       Date:  2008-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.